Member Info for mulledwine

http://www.halifaxmarketwatch.co.uk/rns.cgi?username=&ac=&action=news&rns=1&view=full&story_id=5172745

Evolution Securities raises target from 530p to 550p, buy rating retained.

Credit Suisse downgrades from outperform to neutral, target cut from 280p to 250p.

Credit Suisse upgrades from neutral to outperform, target raised from 240p to 290p.

ubs downgrades from neutral to sell, target slashed from 420p to 100p.

Credit Suisse keeps at outperform, lowers target to 420p from 510p

Spirit Pub Company's outgoing chief executive Ian Dyson has purchased £58,575 worth of shares just days before he exits the company. The director, who is leaving the firm after just over a year in the job, bought up 150,000 shares at 39.05p.

Shares in RTI Capital Partners (RCP) dropped 45p to 1,260p on news that the investment trust's net asset value fell 9.6% to 1,165.9p per share over the six months ended 30th September. In response to the increased market volatility, the group has cut its exposure to industrial commodities and emerging markets, while increasing short futures positions and gold investments.

http://www.investegate.co.uk/Article.aspx?id=201111290700189293S

Resolution Limited ("Resolution" or the "Company") 29 November 2011 Update on delivery of capital synergies and separation from AXA UK Resolution is pleased to announced that on 18 November 2011, the High Court approved a Part VII scheme ("the Scheme") to transfer certain businesses to Friends Provident Life and Pensions Limited, the main UK life assurance company owned by the Company's subsidiary, Friends Life Group plc ("FLG"). The Scheme will take effect from 1 December 2011 and completes the delivery of planned capital synergies for 2011 as set out in the Company's "UK Life Project - Cash and Capital Update" on 7 June 2011. The delivery of these capital synergies was required to enable the Company to undertake a further £250 million cash return to shareholders in 2012, subject to market conditions and regulatory approvals. The Company is also pleased to announce that FLG will acquire Winterthur Life UK Limited from AXA UK on 30 November 2011. This transaction, which completes the acquisition of companies from AXA UK announced in June 2010, follows completion of two other Part VII schemes to transfer out certain portfolios of business which the Company did not wish to acquire. From 1 December 2011, the Company no longer has any material operations classified as "held for sale".

http://www.investegate.co.uk/Article.aspx?id=201111290700139253S

James Murdoch has been re-elected as chairman of British Sky Broadcasting (BSY), although 18.76% of shareholders voted against him. The son of infamous media mogul Rupert Murdoch has been under scrutiny over his possible awareness of the phone hacking scandals that resulted in the demise of the newspaper News of the World. No doubt the vote was helped along by the 39% holding of his father's News Corp. Shares in BSkyB crept down 0.5p to 745p

http://www.investegate.co.uk/Article.aspx?id=201111291130029592S

AstraZeneca (AZN) has been granted marketing approval from the European Commission for its Komboglyze tablet. The medication is designed to be taken in conjunction with diet and exercise as a treatment for type 2 diabetes, a condition which is estimated to affect nearly 53 million people in Europe aged 20-79. The shares inched up 19.5p to 2,840.5p.

http://www.investegate.co.uk/Article.aspx?id=201111290700209466S

Atkins (ATK) kept its "buy" rating from Brewin Dolphin, with a target price of 742p. The engineering consultancy's 65 million pound contract win in Qatar impressed the broker, justifying its focus on the Middle East region. Brewin notes that the contract accounts for 7% of its 180 million pound target for revenues from the region in 2013. Furthermore, the broker expects Atkins to benefit from the 30 billion pound accelerated infrastructure spend in the UK, part of the government's 200 billion pound project that will last until 2015. The shares grew 6.5p to 625p.

Panmure Gordon maintained its "sell" recommendation for Homeserve (HSV), with a 190p target price. The embarrassed insurance company has been fined 85,000 dollars (54,414 pounds) for "deceptive marketing" in the US and the broker believes that the group is struggling to adjust its strategies for different regions. Additionally, Panmure expects the miss selling issues in the UK to weigh down the price for some time. Homeserve shares rose 8.4p to 248.9p.

Northland Capital initiated coverage of landscaping group Marshalls (MSLH), with a 105p target price. The broker noted that the group achieved increased deliveries in the domestic and public & commercial sectors in a flat market, and believes that the householder market is stabilising. Northland added that the firm has been able to offset weak trading conditions through cost reduction and product development. The broker also mentions that while the company's decision to enter the European market is intriguing, it could dilute margins in the short term. The shares jumped 1.75p to 93.25p.

Singer Capital reiterated its "sell" recommendation for Carpetright (CPR) with a reduced target price of 315p, from 465p. The broker expects the flooring specialist to report pre-tax profits of just 1.2 million pounds over the first six months of its financial year, compared to 10 million pounds last year. Singer adds that this is largely attributable to a dismal UK performance, with like-for-like sales down 3% and gross margins declining 400 basis points, although the broker notes that this was partly offset by a 4 million pound cost saving. Shares in Carpetright lifted 11.1p to 386.1p.

Outlook The Group has enjoyed a strong recovery in its core Moscow market. The regional markets in Russia have also enjoyed a recovery and the adjacent CIS markets are now showing improving results, albeit not yet as strongly as in Russia. There is expected to be further economic growth in Russia this year as well as a continuation of the recovery in the CIS markets. At 25 November, forward bookings are £93 million which is in line with the Board's expectations and on a like-for-like basis represents growth of circa 8% over last year's revenues booked at the same time. The Group has a strong portfolio of exhibitions in emerging and growing markets. With its cash flow and strong balance sheet, the Group is in an excellent position to continue to grow its business both organically and through selective acquisitions. The Board remains focused on executing its strategy and, whilst ITE is not immune to changes in the world economy, the Board remains confident of the Group's future prospects.